Breast Cancer Flashcards

1
Q

1.Identify common risk factors associated with breast cancer.

A

Age, family history, high dose estrogen exposure, diet, not having children

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q
  1. Describe and apply available cancer screening guidelines to an individual at average and high risk for developing breast cancer
A

Breast exam, mammogram
Biopsy for staging
CT will show if its metastatic or not
IHC testing: detects protein overexpression if patient is 1+ HER2 low, 2+ should do fish testing, 3+ high and HER2 therapy is needed
FISH - detects gene amplification

Oncotype DX: tests patients recurrence risk, only in select patients (stage I and II, lymph node negative or few, ER positive, or HER2 negative)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q
  1. Generate a treatment plan for breast cancer prevention.
A

self breast exams starting at age 20
Clinical examinations
Start mammogram annually at age 40

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q
  1. Evaluate specific factors in a patient case to generate a breast cancer treatment plan
A

need to determine if patient is pre or postmenopausal
Need to know if patient is ER and PR positive or HER2 positive

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q
  1. Evaluate specific factors in a patient case to develop a breast cancer treatment plan
    in metastatic disease.
A

depends on ER/PR positive or not
if it is we want to do hormone therapy
If this patient has bone disease we can add bisphosphonates as well

For ER/PR negative it depends on if they are HER2 positive if they are we want to do HER2 therapy with chemo
If patient is HER2 negative we want to do chemotherapy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

what are the two types of Invasive Breast cancers

A

Invasive Ductal carcinoma - most common

Invasive lobular carcinoma- second most common

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

what are the two types of Non-invasive breast cancer

A

Ductal carcinoma in situ (DCIS) - have not invaded through the basement membrane

Lobular carcinoma in situ (LCIS) - have not invaded through the basement membrane

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Inflammatory Breast cancer

A

Very aggressive form of breast cancer with rapid onset and poor prognosis

redness, swelling, warmth, inflamed (boob looks like an orange)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

ONCOTYPE DX testing results

A

If score is less than 26 you can do hormone therapy alone

if its greater than 26 chemotherapy and hormonal therapy together

-EXCEPTION: if patient is <50 and has a score of 16-24 they will benefit from chemo and hormonal therapy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

When to give Neoadjuvant therapy (before surgery)

A

for those with a tumor larger than 1cm

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Hormone positive, lymph node - and +, HER2 negative

A

Tumor less than or equal to 0.5cm : Adjuvant endocrine therapy

Tumor greater than 0.5cm or 1-3 positive nodes: DO Oncotype dx testing
if patients score is less than 26: adjuvant endocrine therapy

if patients score is greater than 26: Adjuvant chemo followed by endocrine therapy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Hormone positive, lymph node - and +, HER2 POSITIVE

A

Tumor less than or equal to 0.5cm: Adjuvant endocrine therapy +/- chemo with HER2 targeted therapy

Tumor larger than 0.6cm: Adjuvant chemo with HER2 targeted therapy followed by endocrine therapy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Adjuvant Hormonal therapy options for premenopausal

A

Surgical ablation: remove the ovaries

Tamoxifen: SERM SE: Hot flashes
Leuprolide: LHRH analog
Goserelin: LHRH analog

can do LHRH analog with Aromatase inhibitor but aromatase inhibitor alone is not for premenopausal

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Adjuvant Hormonal therapy options for postmenopausal

A

Tamoxifen: SERM SE Hot flashes

Anastrozole: AI

Letrozole:AI

Exemestane: steroidal AI

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

GUIDELINE DIAGNOSIS - Premenopausal

A

Premenopausal at diagnosis
- Tamoxifen for 5 years +/- leuprolide
OR
- leuprolide and anastrozole/letrozole/ exemestane for 5 years

After 5 years - can continue tamoxifen if patient is still premenopausal for another 5 years
OR
if patient is postmenopausal can consider doing aromatase inhibitor for 5 more years OR tamoxifen for 5 more years

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

GUIDELINE DIAGNOSIS - Postmenopausal

A

Aromatase inhibitor for 5 years

After 5 years - continue aromatase inhibitor

17
Q

Adjuvant chemotherapy regimens
HER2 negative patients with oncotype score greater than 26 (or those 16-25YO)

A

2 prefered options

Dose dence AC:
Doxorubicin, cyclophosphamide (must give growth factors- filgrastim) followed by paclitaxel

TC:
Docetaxel, cyclophosphamide

GIVE TC to patients who have history of cardiotoxicity

18
Q

Adjuvant HER2 positive regimens

A

APT
Paclitaxel, Trastuzumab followed by trastuzumab for 1 year

TCH+ Pertuzumab
Docetaxel, carboplatin, trastuzumab, pertuzumab followed by trastuzumab and pertuzumab for 1 year

APT is good for older patients that might not handle the more aggressive TCH regimen

19
Q

HER2 positive treatment for residual disease

A

once patient has completed 6 cycles of chemo and been on HER2 positive targeted therapy for over a year if they still have cancer present then we would treat with a ado-trastuzumab conjugate for 1 year again

20
Q

Adjuvant therapy for hormone negative, HER2 negative cancer

A

Pembrolizumab + chemotherapy:
Paclitaxel, carboplatin, pembrolizumab (Immunotherapy) for 3 weeks followed by doxorubicin, cyclophosphamide and pembrolizumab
followed with pembrolizumab for 1 year

21
Q

Metastatic Disease
ER/PR+, Bone Mets, Asymptomatic visceral disease

A

Hormone therapy +/- bisphosphonate (bone disease) or denosumab

22
Q

Metastatic disease
ER/PR- symptomatic visceral disease, or hormone refractory

A

HER2 + : HER2 therapy +/- chemo (Trastuzumab, Pertuzumab, docetaxel x every 3 weeks)

HER2- : Chemotherapy

23
Q

Tx for metastatic pts who are HER2 low and have failed multiple treatments

A

Fam-Trastuzumab deruxtecan
can cause interstitial lung disease so if patient is complaining of SOB D/C the drug immediately

24
Q

Metastatic Triple negative therapy

A

Carboplatin is first line

assess PD-1 status and positive score if patient has greater than 10 score they can benefit from pembrolizumab and chemotherapy

25
Q

Hormonal therapy for metastatic HER2 negative and postemnopausal or premenopausal recieving ovarian supression

A

first line treatment

Aromatase inhibitor + palbociclib or abemaciclib (before starting these CDK inhibitors you need to get a complete blood count) (abemaciclib cause diarrhea and ribociclib causes QTc prolongation